Cannovum Cannabis Past Earnings Performance

Past criteria checks 0/6

There is insufficient data on Cannovum Cannabis's performance over the last few years.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals Industry Growth	7.3%
Revenue growth rate	n/a
Return on equity	n/a
Net Margin	n/a
Last Earnings Update	30 Jun 2022

Recent past performance updates

No updates

Recent updates

In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cannovum Cannabis has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.

Show section

Revenue & Expenses Breakdown

How Cannovum Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:27N0 Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 22	0	0	0	0
31 Mar 22	0	0	0	0
31 Dec 21	0	0	0	0
30 Sep 21	0	0	0	0
30 Jun 21	0	0	0	0
31 Mar 21	0	0	0	0
31 Dec 20	0	0	0	0
31 Dec 19	0	0	0	0

Quality Earnings: Insufficient data to determine if 27N0 has high quality earnings.

Growing Profit Margin: Insufficient data to determine if 27N0's profit margins have improved over the past year.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 27N0's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare 27N0's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if 27N0's earnings growth over the past year exceeded the Pharmaceuticals industry average.

Return on Equity

High ROE: 27N0 has a negative Return on Equity (0%), as it is currently unprofitable.